Search the Newsreel

Biodesix Inc (BDSX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Biodesix Inc.'s (BDSX) shareholder structure, detailing major individual and institutional holdings. Key shareholders include Jack W. Schuler and Lawrence T. Kennedy Jr., alongside institutional holdings from various investment types. The data also presents historical institutional shareholding trends and …

Biodesix Inc (BDSX) Cash Flow

This article provides detailed annual and quarterly cash flow statements for Biodesix Inc (BDSX), allowing investors to evaluate the company's financial health. It breaks down operating, investing, and financing cash flows, along with changes in working capital and capital expenditures. The report also includes …

Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Biodesix Inc (BDSX), noting its current valuation score of 8.53, ranking 32nd in the Healthcare Providers & Services industry. It details the company's P/E ratio of -5.31, which is significantly below its recent high and above its …

Biodesix Inc (BDSX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of dividends and stock splits for Biodesix Inc (BDSX). It states that the company has distributed $0.00 in dividends over the past five years. The only recorded stock split event is a 20-to-1 merger scheduled for September 11, …

Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Biodesix Inc (BDSX), noting its current financial score is 7.18, ranking 52 out of 75 in the Healthcare Providers & Services industry, indicating a weak financial status but average operating efficiency. The company recently reported a 42.30% …

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

The article compares bioAffinity Technologies (BIAF) and Biodesix (BDSX), two cancer diagnostics companies. While BIAF specializes in non-invasive lung cancer diagnostics and is in an earlier commercial stage with higher risk, BDSX has a more established commercial portfolio and diversified revenue streams through its …

BDSX|Biodesix Inc|Price:22.000|Chg%:-0.320

Biodesix Inc (BDSX) closed at $22.00, down 1.43%, with a market cap of $222.36 million. Analysts rate the stock as a "Buy" with a target price of $28.75, implying a potential 28.81% upside. The company shows strong fundamentals and high growth potential, despite recent …

Biodesix to report Q2FY26 results on August 5, 2026

Biodesix, Inc., a diagnostic solutions company specializing in lung disease, announced it will release its financial results for the second quarter ended June 30, 2026, after the close of trading on August 5, 2026. The company will also host a conference call and webcast …

Biodesix management will give a business update on Aug. 5

Biodesix (Nasdaq: BDSX) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss results and provide a business …

Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Analysts have assigned Biodesix, Inc. (NASDAQ:BDSX) a consensus rating of "Moderate Buy," with an average 12-month price target of $28.33. This rating comes from five analysts, with three recommending a buy, one a strong buy, and one a sell. The company's recent earnings report …

Biodesix Inc. (BDSX) Gains Momentum: Key Levels to Watch After 3% Rally - Common Gap

BDSX Forecast — Price Target — Prediction for 2027

Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions

Biodesix stock price target raised to $22 by Canaccord on revenue growth

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target

Biodesix, Inc. Reports Estimated Q4 2025 Revenue of $28.8 Million, Achieving 41% Growth and Full-Year Revenue of $88.5 Million, Up 24%